Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15653278 | 0.79 | KDM1A (0.41) | KDM1AMAOBCYP1A2CYP2D6KDM4E | |
| SCHEMBL13708409 | 0.79 | GAA (0.36) | KDM1AMAOBKMT2A | |
| SCHEMBL30842427 | 0.76 | KDM1A (0.33) | KDM1AMAOB | |
| SCHEMBL15653706 | 0.69 | EPHX1 (0.34) | KDM4EKMT2AEPHX1 | |
| SCHEMBL21828806 | 0.69 | ARG1 (0.36) | KDM1AMAOBEPHX1 | |
| SCHEMBL18394460 | 0.69 | CYP2C19 (0.61) | KDM1AMAOBCYP1A2KDM4E | |
| SCHEMBL15653919 | 0.68 | EPHX1 (0.39) | KDM1AMAOBCYP1A2CYP2D6KDM4E | |
| Hydrochloric Acid SCHEMBL29031078 | 0.67 | CYP2C19 (0.58) | KDM1AMAOBCYP1A2KDM4E | |
| SCHEMBL31405399 | 0.67 | GRM2 (0.46) | KDM4EKMT2A | |
| SCHEMBL904126 | 0.67 | ESR1 (0.36) | KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592334-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-20080139540-A1 | 6-[({3-hydroxy-8-[6-(methyloxy)-1,5-naphthyridin-4-yl]-8-azaspiro[4.5]dec-2-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]thiazin-3-on; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| EP-1846418-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006081182-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139540-A1 | 6-[({3-hydroxy-8-[6-(methyloxy)-1,5-naphthyridin-4-yl]-8-azaspiro[4.5]dec-2-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]thiazin-3-on; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NT5C3B, NT5C, SPOUT1 | KDM1A 1506/4885MAOB 1110/4885CYP1A2 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.